{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:19:15Z","timestamp":1778624355299,"version":"3.51.4"},"reference-count":45,"publisher":"The Royal Society","issue":"1416","license":[{"start":{"date-parts":[[2001,12,29]],"date-time":"2001-12-29T00:00:00Z","timestamp":1009584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/royalsociety.org\/journals\/ethics-policies\/data-sharing-mining\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Phil. Trans. R. Soc. Lond. B"],"published-print":{"date-parts":[[2001,12,29]]},"abstract":"<jats:p>The development of the neuraminidase inhibitors has revolutionized the management options for influenza. Zanamivir was the first such inhibitor to be approved for the treatment of influenza in humans. It is delivered by inhalation to the respiratory tract, which is the site of viral replication, in order to ensure immediate antiviral activity. Early treatment with zanamivir in clinical trials rapidly reduced the severity and duration of influenza symptoms and associated complications. Furthermore, chemoprophylaxis with zanamivir was shown to be effective in the prevention of influenza illness. To date, there is no evidence for the emergence of clinically significant zanamivir\u2013resistant isolates. In conclusion, zanamivir offers a useful complementary strategy to vaccination in the effective management of influenza.<\/jats:p>","DOI":"10.1098\/rstb.2001.1021","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T19:57:35Z","timestamp":1027713455000},"page":"1885-1893","source":"Crossref","is-referenced-by-count":33,"title":["Zanamivir: from drug design to the clinic"],"prefix":"10.1098","volume":"356","author":[{"given":"Michael","family":"Elliott","sequence":"first","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, NC 27709, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"175","published-online":{"date-parts":[[2001,12,29]]},"reference":[{"key":"p_1","doi-asserted-by":"crossref","unstructured":"Belshe R. B. Burk B. Newman F. Cerruti R. L. & Sim I. S. 1989 Resistance of in\u00a3uenza A virus to amantadine and rimantadine: results of one decade of surveillance. J. Infect. Dis. 159 430^435.","DOI":"10.1093\/infdis\/159.3.430"},{"key":"p_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003088-199936001-00003","article-title":"Pharmacoscintigraphic evaluation of Iung deposition of inhaled zanamivir in healthy volunteers","volume":"36","author":"Cass L.","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"p_3","first-page":"19","article-title":"E\u00a1ect of renal impairment on the pharmacokinetics of intravenous zanamivir","volume":"36","author":"Cass L. M.","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"p_4","first-page":"11","article-title":"Pharmacokinetics of zanamivir after intravenous oral inhaled or intranasal administration to healthy volunteers","volume":"36","author":"Cass L. M.","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"p_5","doi-asserted-by":"crossref","unstructured":"Cass L. M. R. Gunawardena K. A. Macmahon M. M. & Bye A. 2000b Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respirat. Med. 94 166^173.","DOI":"10.1053\/rmed.1999.0718"},{"key":"p_6","unstructured":"Daniel M. J. Harker A. J. & Gray D. M. 1996 Preclinical disposition studies of GG167 a novel anti-in\u00a3uenza agent. Opt. Control In\u00a3uenza 70 A70."},{"key":"p_7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2165\/00003088-199936001-00005","article-title":"The low potential for drug interactions with zanamivir","volume":"36","author":"Daniel M. J.","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"p_8","doi-asserted-by":"crossref","unstructured":"Dines G. D. Bethell R. & Daniel M. 1998 Preclinical development of low toxicity drugs: focus on zanamivir an antiin\u00a3uenza drug. Drug Safety 19 233^241.","DOI":"10.2165\/00002018-199819030-00006"},{"key":"p_9","doi-asserted-by":"crossref","unstructured":"Freund B. Gravenstein S. Elliott M. & Miller I. 1999 Zanamivir: a review of clinical safety. Drug Safety 21 267^281.","DOI":"10.2165\/00002018-199921040-00003"},{"key":"p_10","unstructured":"Gravenstein S. Drinka P. Osterweil D. Schilling M. McElhaney J. Elliott M. Hammond J. Keene O. Krause P. & Flack N. 2000 A multicentre prospective double-blind controlled trial comparing the relative safety of zanamivir to rimantadine for nursing home in\u00a3uenza outbreak control. In 40th Interscience Conference on Antimicrobial Agents and Chemotherapy A270."},{"key":"p_11","doi-asserted-by":"crossref","unstructured":"Gubareva L. V. Bethell R. Hart G. J. Murti K. G. Penn C. R. & Webster R. G. 1996 Characterization of mutants of in\u00a3uenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 70 1818^1827.","DOI":"10.1128\/JVI.70.3.1818-1827.1996"},{"key":"p_12","doi-asserted-by":"crossref","unstructured":"Gubareva L. V. Matrosovich M. N. Brenner M. K. Bethell R. C. & Webster R. G. 1998 Evidence for zanamivir resistance in an immunocompromised child infected with in\u00a3uenza B virus. J. Infect. Dis. 178 1257^1262.","DOI":"10.1086\/314440"},{"key":"p_13","doi-asserted-by":"crossref","unstructured":"Hayden F. G. 1994 Amantadine and rimantadine resistance in in\u00a3uenza A viruses. Curr. Opin. Infect. Dis. 7 674^677.","DOI":"10.1097\/00001432-199412000-00008"},{"key":"p_14","doi-asserted-by":"crossref","unstructured":"Hayden F. G. Gwaltney Jr J. M. Van de Castle R. L. Adams K. F. & Giordani B. 1981 Comparative toxicity of amantadine hydrochloride and rimantadine hydro-chloride in healthy adults. Antimicrob. Agents Chemother. 19 226^233.","DOI":"10.1128\/AAC.19.2.226"},{"key":"p_15","doi-asserted-by":"crossref","unstructured":"Hayden F. G. Ho\u00a1man H. E. & Spyker D. A. 1983 Di\u00a1erences in side e\u00a1ects of amantadine hydrochloride and rimantadine hydrochloride relate to di\u00a1erences in pharmacokinetics. Antimicrob. Agents Chemother. 23 458^464.","DOI":"10.1128\/AAC.23.3.458"},{"key":"p_16","doi-asserted-by":"crossref","unstructured":"Hayden F. G. Belshe R. B. Clover R. D. Hay A. J. Oakes M. G. & Soo W. 1989 Emergence and apparent transmission of rimantadine-resistant in\u00a3uenza A virus in families. N. Engl. J. Med. 321 1696^1702.","DOI":"10.1056\/NEJM198912213212502"},{"key":"p_17","doi-asserted-by":"crossref","unstructured":"Hayden F. G. Rollins B. S. & Madren L. K. 1994 Antiin\u00a3uenza virus activity of the neuraminidase inhibitor 4- guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res. 25 123^131.","DOI":"10.1016\/0166-3542(94)90101-5"},{"key":"p_18","doi-asserted-by":"crossref","unstructured":"Hayden F. G. Treanor J. J. Betts R. F. Lobo M. Esinhart J. D. & Hussey E. K. 1996a Safety and e\u00a4cacy of the neuraminidase inhibitor GG167 in experimental human in\u00a3uenza. J. Am. Med. Assoc. 275 295^299.","DOI":"10.1001\/jama.275.4.295"},{"key":"p_19","unstructured":"Hayden F. Lobo M. Hussey E. & Eason C. 1996b E\u00a4cacy of intranasal zanamivir in experimental human in\u00a3uenza A and B virus infection. In Options for control of in\u00a3uenza III (ed. L. Brown A. Hampson & A. Webster) pp. 718^725. Amsterdam The Netherlands: Elsevier Science BV."},{"key":"p_20","doi-asserted-by":"crossref","unstructured":"Hayden F. G. Osterhaus A. D. Treanor J. J. Fleming D. M. Aoki F. Y. Nicholson K. G. Bohnen A. M. Hirst H. M. Keene O. & Wightman K. 1997 E\u00a4cacy and safety of the neuraminidase inhibitor zanamivir in the treatment of in\u00a3uenza virus infections. GG167 In\u00a3uenza Study Group. N. Engl. J. Med. 337 874^880.","DOI":"10.1056\/NEJM199709253371302"},{"key":"p_21","doi-asserted-by":"crossref","unstructured":"Hayden F. G. Gubareva L. V. Monto A. S. Klein T. C. Elliott M. J. Hammond J. M. Sharp S. J. & Ossi M. J. 2000 Inhaled zanamivir for the prevention of in\u00a3uenza in families. N. Engl. J. Med. 343 1282^1289.","DOI":"10.1056\/NEJM200011023431801"},{"key":"p_22","doi-asserted-by":"crossref","unstructured":"Hedrick J. A. Barzilai A. Behre U. Henderson F. W. Hammond J. Reilly L. & Keene O. 2000 Zanamivir for treatment of symptomatic in\u00a3uenza A and B infection in children \u00a2ve to twelve years of age: a randomized controlled trial. Pediatr. Infect. Dis. J. 19 410^417.","DOI":"10.1097\/00006454-200005000-00005"},{"key":"p_23","doi-asserted-by":"crossref","unstructured":"Holzer C. T. Von Itzstein M. Jin B. Pegg M. S. Stewart W. P. & Wu W. Y. 1993 Inhibition of sialidases from viral bacterial and mammalian sources by analogues of 2-deoxy-2 3-didehydro-N-acetylneuraminic acid modi\u00a2ed at the C-4 position. GlycoconjugateJ. 10 40^44.","DOI":"10.1007\/BF00731185"},{"key":"p_24","first-page":"336","article-title":"Zanamivir for the treatment of clinically diagnosed in\u00a3uenza in clinical practice: results of the Valuable-Insights-from-Patients","volume":"20","author":"Johnson R.","year":"2000","journal-title":"Study. Clin. Drug Invest."},{"key":"p_25","unstructured":"Lalezari J. Klein T. Stapleton J. Elliott M. Flack N. & Keene O. 1999 The e\u00a4cacy and safety of inhaled zanamivir in the treatment of in\u00a3uenza in otherwise healthy and high risk individuals in North America. J. Antimicrob. Chemother. 44 p. 42."},{"key":"p_26","doi-asserted-by":"crossref","unstructured":"Lalezari J. Campion K. Keene O. & Silagy C. 2001 Zanamivir for the treatment of in\u00a3uenza A and B infection in high-risk patients\u00f6a pooled analysis of randomized controlled trials. Arch. Intern. Med. 161 212^217.","DOI":"10.1001\/archinte.161.2.212"},{"key":"p_27","doi-asserted-by":"crossref","unstructured":"McBean A. M. Babish J. D. & Warren J. L. 1993 The impact and cost of in\u00a3uenza in the elderly. Arch. Intern. Med. 153 2105^2111.","DOI":"10.1001\/archinte.153.18.2105"},{"key":"p_28","doi-asserted-by":"crossref","unstructured":"McKimm-Breschkin J. L. 2000 Resistance of in\u00a3uenza viruses to neuraminidase inhibitors\u00f6a review. Antiviral Res. 47 1^17.","DOI":"10.1016\/S0166-3542(00)00103-0"},{"key":"p_29","doi-asserted-by":"crossref","unstructured":"Makela M. J. Pauksens K. Rostila T. Fleming D. M. Man C. Y. Keene O. N. & Webster A. 2000 Clinical e\u00a4cacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of in\u00a3uenza: a randomized double-blind placebo-controlled European study. J. Infect. 40 42^48.","DOI":"10.1053\/jinf.1999.0602"},{"key":"p_30","doi-asserted-by":"crossref","unstructured":"Matsumoto K. (and 12 others) 1999 Safety and e\u00a4cacy of the neuraminidase inhibitor zanamivir in treating in\u00a3uenza virus infection in adults: results from Japan. GG167 Group. Antiviral Ther. 4 61^68.","DOI":"10.1177\/135965359900400202"},{"key":"p_31","doi-asserted-by":"crossref","unstructured":"Monto A. S. Fleming D. M. Henry D. De Groot R. Makela H. Klein T. Elliott M. Keene O. N. & Man C. Y. 1999a E\u00a4cacy and safety of the neuraminidase inhibitor zanamivir in the treatment of in\u00a3uenza A and B virus infections. J. Infect. Dis. 180 254^261.","DOI":"10.1086\/314904"},{"key":"p_32","doi-asserted-by":"crossref","unstructured":"Monto A. S. Webster A. & Keene O. 1999b Randomized placebo-controlled studies of inhaled zanamivir in the treatment of in\u00a3uenza A and B: pooled e\u00a4cacy analysis. J. Antimicrob. Chemother. 44 23^29.","DOI":"10.1093\/jac\/44.suppl_2.23"},{"key":"p_33","doi-asserted-by":"crossref","unstructured":"Monto A. S. Robinson D. P. Herlocher M. L. Hinson Jr J. M. Elliott M. J. & Crisp A. 1999c Zanamivir in the prevention of in\u00a3uenza among healthy adults: a randomized controlled trial. J. Am. Med. Assoc. 282 31^35.","DOI":"10.1001\/jama.282.1.31"},{"key":"p_34","doi-asserted-by":"crossref","unstructured":"Murphy K. R. Eivindson A. Pauksens K. Stein W. J. Tellier G. W. Leophonte P. Sharp S. J. & Loeschel E. 2000 E\u00a4cacy and safety of inhaled zanamivir for the treatment of in\u00a3uenza in patients with asthma or chronic obstructive pulmonary disease\u00f6a double-blind randomised placebocontrolled multicentre study. Clin. Drug Invest. 20 337^349.","DOI":"10.2165\/00044011-200020050-00005"},{"key":"p_35","doi-asserted-by":"crossref","unstructured":"Osterhaus A. Hedrick J. Henrickson K. Makela M. J. Webster A. & Keene O. 2000 Clinical e\u00a4cacy of inhaled zanamivir for the treatment of patients with in\u00a3uenza B virus infection. Clin. Drug Invest. 20 223^228.","DOI":"10.2165\/00044011-200020040-00003"},{"key":"p_36","doi-asserted-by":"crossref","unstructured":"Peng A. W. Milleri S. & Stein D. S. 2000a Direct measurement of the anti-in\u00a3uenza agent zanamivir in the respiratory tract following inhalation. Antimicrob. Agents Chemother. 44 1974^1976.","DOI":"10.1128\/AAC.44.7.1974-1976.2000"},{"key":"p_37","doi-asserted-by":"crossref","unstructured":"Peng A. W. Hussey E. K. Rosolowski B. & Blumer J. L. 2000b Pharmacokinetics and tolerability of a single inhaled dose of zanamivir in children. Curr. Ther. Res. Clin. Exp. 61 36^46.","DOI":"10.1016\/S0011-393X(00)88495-7"},{"key":"p_38","doi-asserted-by":"crossref","unstructured":"Ryan D. M. Ticehurst J. Dempsey M. H. & Penn C. R. 1994 Inhibition of in\u00a3uenza virus replication in mice by GG167 (4- guanidino-2 4-dideoxy-2 3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother. 38 2270^2275.","DOI":"10.1128\/AAC.38.10.2270"},{"key":"p_39","doi-asserted-by":"crossref","unstructured":"Ryan D. M. Ticehurst J. & Dempsey M. H. 1995 GG167 (4- guanidino-2 4-dideoxy-2 3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of in\u00a3uenza virus in ferrets. Antimicrob. Agents Chemother. 39 2583^2584.","DOI":"10.1128\/AAC.39.11.2583"},{"key":"p_40","doi-asserted-by":"crossref","unstructured":"Silagy C. & Watts R. 2000 Zanamivir a new targeted therapy in the treatment of in\u00a3uenza\u00f6a patient perspective assessed by questionnaire. Clin. Drug Invest. 19 111^121.","DOI":"10.2165\/00044011-200019020-00004"},{"key":"p_41","doi-asserted-by":"crossref","unstructured":"The Management of In\u00a3uenza in the Southern Hemisphere Trialists Study Group. 1998 Randomised trial of e\u00a4cacy and safety of inhaled zanamivir in treatment of in\u00a3uenza A and B virus infections. Lancet 352 1877^1881.","DOI":"10.1016\/S0140-6736(98)10190-3"},{"key":"p_42","doi-asserted-by":"crossref","unstructured":"Von Itzstein M. (and 17 others) 1993 Rational design of potent sialidase-based inhibitors of in\u00a3uenza virus. Nature 363 418^423.","DOI":"10.1038\/363418a0"},{"key":"p_43","doi-asserted-by":"crossref","unstructured":"Whittington A. & Bethell R. 1995 Recent developments in antiviral therapy of in\u00a3uenza. Expert. Opin. Ther. Patents 5 793^803.","DOI":"10.1517\/13543776.5.8.793"},{"key":"p_44","doi-asserted-by":"crossref","unstructured":"Woods J. M. (and 10 others) 1993 4-Guanidino-2 4-dideoxy-2 3-dehydro-N-acetylneuraminic acid is a highly e\u00a1ective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of in\u00a3uenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37 1473^1479.","DOI":"10.1128\/AAC.37.7.1473"},{"key":"p_45","unstructured":"Zimmerman R. K. Ruben F. L. & Ahwesh E. R. 1997 In\u00a3uenza in\u00a3uenza vaccine and amantadine\/rimantadine. J. Family Pract. 45 107^122."}],"container-title":["Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/doi\/pdf\/10.1098\/rstb.2001.1021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/royalsocietypublishing.org\/doi\/pdf\/10.1098\/rstb.2001.1021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:22:31Z","timestamp":1778620951000},"score":1,"resource":{"primary":{"URL":"http:\/\/royalsocietypublishing.org\/rstb\/article\/356\/1416\/1885-1893\/19959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12,29]]},"references-count":45,"journal-issue":{"issue":"1416","published-print":{"date-parts":[[2001,12,29]]}},"alternative-id":["10.1098\/rstb.2001.1021"],"URL":"https:\/\/doi.org\/10.1098\/rstb.2001.1021","relation":{},"ISSN":["0962-8436","1471-2970"],"issn-type":[{"value":"0962-8436","type":"print"},{"value":"1471-2970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12,29]]}}}